Strategic investment from Goldman Sachs Alternatives and additional credit facility commitments fortify BrightNight's standing as a leading U.S. renewable power...
Hemogenyx Pharmaceuticals announces a strategic investment from Prevail Partners, , totaling $350,000 (£269,000) through a...
Effective October 1, 2024, David Nirtaut, Co-Chief Investment Officer, will be elevated to the sole Chief Investment Officer of Mesirow...
Proven Conversational AI Solution Supports Next Generation of Population Health Management NEW YORK, Sept. 5, 2024 /PRNewswire/ -- WindRose Health...
Opportunistic capital raise on attractive terms Accelerates capital and earnings improvement; capital raise estimated to result in pro forma CET1...
Significant capacity improvements will enhance critical rail corridor, open additional opportunities for statewide business and economic growth ATLANTA, Aug. 1, 2024...
